Laboratory for Clinical Research of Vascular and Heart Diseases












            ******************************************************************************************

            *
            ******************************************************************************************




            ******************************************************************************************

            * Offer
            ******************************************************************************************
            - Screening and longitudinal follow-up of subjects at risk of cardiovascular diseases (CVD

            with manifest CVD
            - Genetic studies of subjects at risk and patients with CVD

            - Phase II–IV pharmacologic studies in cardiovascular medicine
            - Research on blood pressure (BP) and hypertension, focused on BP measurement, genetics of
            pharmacology of hypertension, arterial stiffness

            - Research on arterial properties with noninvasive methods: arterial stiffness, endothelia
            intima-media thickness of carotid artery
            - Research on biological markers of CVD in collaboration with different labs; e.g., marker

            calcification, accelerated atherosclerosis, subclinical myocardial ischemia, nutrition par
            - Statistical analysis of the data performed primarily by the physicians who do the resear
            analysis is consulted with statisticians






            ******************************************************************************************
            * Expertise

            ******************************************************************************************
            - Prevention
            - Clinical physiology

            - Hharmacology of vascular and heart diseases





            ******************************************************************************************

            * Membres
            ******************************************************************************************
            - Prof. Jan Filipovský, M.D., Ph.D. – Research Group Leader

            - Věra Běšťáková
            - Július Gelžinský, M.D.
            - Assoc. Prof. Jana Hirmerová, M.D., Ph.D.

            - Monika Choltová
            - Petra Karnosová, M.D.
            - Assoc. Prof. Radek Kučera, M.D., Ph.D.

            - Štěpán Mareš, M.D.
            - Assoc. Prof. Otto Mayer, M.D., Ph.D.
            - Assoc. Prof. Jitka Mlíková Seidlerová, M.D., Ph.D.

            - Prof. Hana Rosolová, M.D., Ph.D.
            - Veronika Svobodová






            ******************************************************************************************
            * Selected Publications
            ******************************************************************************************

            - Seidlerová J, Filipovský J, Mayer O, Wohlfahrt P, Cífková R.: Positive effects of antihy
            treatment on aortic stiffness in the general population. Hypertens Res. 2014; 37, 64–68
            - Wohlfahrt P, Krajčoviechová A, Seidlerová J, Mayer O, Bruthans J, Filipovský J, Laurent 

            Arterial stiffness parameters: How do they differ? Atherosclerosis 2013; 231: 359–364
            - Mayer O, Seidlerová J, Bruthans J, Filipovský J, Timoracká K, Vaněk J, Černá L, Wohlfahr
            Theuwissen E, Vermeer C.: Desphospho-uncarboxylated matrix Gla-protein is associated with 

            patients with chronic stable vascular disease. Atherosclerosis 2014; 235: 162–168
            - Hirmerová J, Seidlerová J, Šubrt I.: Deep vein thrombosis and/ or pulmonary embolism con
            superficial vein thrombosis of the legs. Cross-sectional single center study of prevalence

            factors. International Angiology 2013; 32: 410–416
            - Seidlerová J, Filipovský J, Mayer O Jr, Kučerová A, Pešta M.: Association between endoth
            polymorphisms and arterial properties in the general population. Nitric Oxide 2015; 44: 47

            - Mayer O Jr, Filipovský J, Pešta M, Cífková R, Dolejšová M, Šimon J.: Synergistic effect 
            II type 1 receptor and endothelial nitric oxide synthase gene polymorphisms on arterial st
            Hypertens. 2008; 22: 111–118

            - De Bacquer D, Dallongeville J, Kotseva K, Cooney MT, Pajak A, Deckers JW, Mayer O, Vanuz
            Fras Z, Östor E, Ambrosio GB, De Backer G, Wood D, Keil U, Sans S, Graham I, Pyörälä K.: R
            cardiovascular mortality in patients with coronary heart disease: the EUROASPIRE Risk Cate

            Cardiol. 2013; 168: 910–914





            ******************************************************************************************

            * Are you interested in this expertise?
            ******************************************************************************************
            Please contact CPPT UK

            Web: www.cppt.cuni.cz/ [ URL "https://cppt.cuni.cz/"]
            Mail: transfer@cuni.cz
            Phone: +420 224 491 255






            ******************************************************************************************
            * Experts and their department

            ******************************************************************************************
            Prof. Jan Filipovský, M.D., Ph.D.
            University Hospital Pilsen – II. Medical Department

            Web: http://www.biomedic-plzen.cz/cz [ URL "http://www.biomedic-plzen.cz/cz"]